These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10071438)

  • 1. High-dose chemotherapy for the treatment of high-risk and advanced breast cancer.
    Burtness B
    Conn Med; 1999 Jan; 63(1):41-6. PubMed ID: 10071438
    [No Abstract]   [Full Text] [Related]  

  • 2. [High-dose chemotherapy for metastatic breast cancer].
    Lalle M; De Rosa L; Perillo A; Scambia G; D'Aprile M; Antimi M
    Clin Ter; 2004; 155(7-8):305-15. PubMed ID: 15553258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dose density and dose intensity in the treatment of breast cancer].
    Saintigny P; Assouad S; Gligorov J; Selle F; Roché H; Breau JL; Morère JF; Lotz JP
    Bull Cancer; 2004 Dec; 91 Suppl 4():S244-53. PubMed ID: 15899616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial regional chemotherapy of advanced breast cancer.
    De Dycker RP; Timmermann J; Neumann RL; Wever H; Schindler AE
    J Chemother; 1989 Jul; 1(4 Suppl):1193-5. PubMed ID: 16312830
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose chemotherapy in breast cancer--a thin red line between hype and hope.
    Toh HC
    Singapore Med J; 2000 Feb; 41(2):86-8. PubMed ID: 11063211
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy for primary breast cancer: facts versus anecdotes.
    Hortobagyi GN
    J Clin Oncol; 1999 Nov; 17(11 Suppl):25-9. PubMed ID: 10630258
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer.
    Malinovszky KM; Gould A; Foster E; Cameron D; Humphreys A; Crown J; Leonard RC;
    Br J Cancer; 2006 Dec; 95(12):1626-31. PubMed ID: 17160080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy for breast cancer.
    Hudis CA; Münster PN
    Semin Oncol; 1999 Feb; 26(1):35-47. PubMed ID: 10073560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of a high dose methotrexate regime in the management of advanced breast cancer.
    Penney GC; Roberts MM
    Clin Oncol; 1980 Dec; 6(4):385-6. PubMed ID: 7460412
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dose-dense chemotherapy in the management of breast cancer.
    Norton L
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.
    Nieboer P; Buijs C; Rodenhuis S; Seynaeve C; Beex LV; van der Wall E; Richel DJ; Nooij MA; Voest EE; Hupperets P; Mulder NH; van der Graaf WT; TenVergert EM; van Tinteren H; de Vries EG
    J Clin Oncol; 2005 Nov; 23(33):8296-304. PubMed ID: 16219926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critique of the high-dose chemotherapy studies in breast cancer: a positive look at the data.
    Antman KH
    J Clin Oncol; 1999 Nov; 17(11 Suppl):30-4. PubMed ID: 10630259
    [No Abstract]   [Full Text] [Related]  

  • 18. [High-dose chemotherapy for breast cancer: are we at the end or at the end of the beginning?].
    Lopez M
    Clin Ter; 1999; 150(4):259-62. PubMed ID: 10605161
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.
    Miller KD; Sledge GW
    Medscape Womens Health; 2000; 5(3):E1. PubMed ID: 11109042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment of postmenopausal women with advanced breast carcinoma.
    Board RE; Dean EJ; Mitchell C; Wardley AM
    Expert Rev Anticancer Ther; 2006 Apr; 6(4):613-24. PubMed ID: 16613548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.